Forecasting drug utilization and expenditure in a metropolitan health region

BMC Health Services Research

Volumn 10, Issue , 2010, Pages

  Wettermark, Björn ^a,b   Persson, Marie E ^a   Wilking, Nils ^c   Kalin, Mats ^a,b   Korkmaz, Seher ^a,b   Hjemdahl, Paul ^b   Godman, Brian ^b,d   Petzold, Max ^e   Gustafsson, Lars L ^a,b  

^a STOCKHOLM COUNTY COUNCIL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG COST; DRUG UTILIZATION; ECONOMICS; FORECASTING; HEALTH CARE COST; HEALTH SERVICE; HUMAN; RESIDENTIAL CARE; STATISTICAL MODEL; SWEDEN;

CATCHMENT AREA (HEALTH); DRUG COSTS; DRUG UTILIZATION; FORECASTING; HEALTH EXPENDITURES; HUMANS; LINEAR MODELS; SWEDEN; URBAN HEALTH SERVICES;

EID: 77954095770     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-10-128     Document Type: Article

References (80)

1. Drug discovery: a historical perspective. J Drews, Science 2000 287 1960 4 10.1126/science.287.5460.1960 10720314
2. Moving towards individualized medicine with pharmacogenomics. WA Evans MV Relling, Nature 2004 429 464 8 10.1038/nature02626 15164072
3. A pharmacogeneticist's look at drug effects and the drug development process: an overview. W Kalow, Exp Opin Pharmacother 2005 6 1299 303 10.1517/14656566.6.8.1299 (Pubitemid 41030889)
4. Personalized medicine: elusive dream or imminent reality? LJ Lesko, Clin Pharmacol Ther 2007 81 807 16 10.1038/sj.clpt.6100204 17505496
5. -2008 FDA drug approvals. B Hughes, Nature reviews 2009 8 93 96 10.1038/nrd2813 19180096
6. Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries. L Garattini N Motterlini D Cornago, Health Policy 2008 85 305 13 10.1016/j.healthpol.2007.08.005 17928092
7. Perspective. Tier 4 drugs and the fraying of the social compact. TH Lee EJ Emanuel, N Engl J Med 2008 359 333 5 10.1056/NEJMp0804261 18650510
8. Modell för strukturerad introduktion av nya läkemedel: syftet är att erbjuda alla patienter ändamålsenlig behandling. LL Gustafsson B Wettermark M Kalin S Korkmaz M Persson H Almkvist P Hjemdahl K Kristianson B Ringertz G Thörnwall-Bergendahl N Wilking, Läkartidningen 2008 105 2917 22 (Model for structured introduction of new drugs: the aim is to offer all patients adequate treatment - in Swedish)
9. Guidelines for ATC classification and DDD assignment. WHO Collaborationg Center for Drug Statistics Methodology, Oslo. World Health Organization, 2008 http://www.whocc.no Accessed at July 30, 2008.
10. Swedish experience in ambulatory care with multifaceted national and regional drug reforms and initiatives: global relevance. B Godman B Wettermark M Hoffmann K Andersson A Haycox LL Gustafsson, Expert Review of Pharmacoeconomics and Outcomes Research 2009 9 65 83 10.1586/14737167.9.1.65 19371180
11. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals. K Andersson G Bergström MG Petzold A Carlsten, Health Policy 2007 81 376 84 10.1016/j.healthpol.2006.07.005 16945449
12. The challenge of biosimilars. H Mellstedt D Niederwieser H Ludwig, Ann Oncol 2008 19 411 9 10.1093/annonc/mdm345 17872902
13. The new Swedish Prescribed Drug Register - Opportunities for pharmacoepidemiological research and experience from the first six months. B Wettermark N Hammar M Fored A Leimanis P Otterblad-Olausson U Bergman I Persson A Sundström B Westerholm M Rosén, Pharmacoepidemiol Drug Saf 2007 16 726 35 10.1002/pds.1294 16897791
14. What drives change? Barriers to and incentives for achieving evidence-based practice. R Grol M Wensing, Med J Aust 2004 180 57 60 15012583
15. Financial incentives linked to self-assessment of prescribing patterns - a new approach for quality improvement of drug prescribing in primary care. B Wettermark Pehrsson M Juhasz-Haverinen M Veg M Edlert G Törnwall-Bergendahl M Almqvist B Godman U Bergman, Quality in Primary Care 2009 17 179 89 19622268
16. Effective early warning systems for new and emerging health technologies: developing an evaluation framework and an assessment of current systems. K Murphy C Packer A Stevens S Simpson, Int J Technol Assess Health Care 2007 23 324 30 10.1017/S0266462307070493 17579934
17. International Diabetes Federation, Diabetes atlas Brussels: International Diabetes Federation 3 2008
18. Three new drugs for type 2 diabetes. Anonymous, Drug Ther Bull 2008 46 49 52 10.1136/dtb.2008.06.0014 18603639
19. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. SE Nissen K Wolski, N Engl J Med 2007 356 2457 71 10.1056/NEJMoa072761 17517853
20. Efficacy and safety of incretin therapy in type 2 diabetes. E Amori J Lau A Pittas, JAMA 2007 298 194 206 10.1001/jama.298.2.194 17622601
21. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. JM Jonassson R Ljung M Talbäck B Haglund S Gudbjörnsdttir G Steineck, Diabetologica 2009 52 1745 54 10.1007/s00125-009-1444-2
22. Orphan drug development is not taking off. R Joppi V Bertele' S Garattini, Br J Clin Pharmacol 2009 67 5 494 502 10.1111/j.1365-2125.2009.03369. x 19552743
23. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. BI Eriksson DJ Quinlan, Drugs 2006 66 1411 29 10.2165/00003495-200666110-00001 16906775
24. New oral anticoagulants in atrial fibrillation. AG Turpie, Eur Heart J 2008 29 155 65 10.1093/eurheartj/ehm575 18096568
25. Dabigatran versus warfarin in patients with atrial fibrillation. SJ Connolly MD Ezekowitz S Yusuf J Eikelboom J Oldgren A Parekh J Pogue PA Reilly E Themeles J Varrone S Wang M Alings D Xavier J Zhu R Diaz BS Lewis H Darius HC Diener CD Joyner L Wallentin RE-LY Steering Committee and Investigators, N Engl J Med 2009 361 1139 51 10.1056/NEJMoa0905561 19717844
26. European guidelines on cardiovascular disease prevention in clinical practice. G De Backer E Ambrosioni K Borch-Johnsen C Brotons R Cifkova J Dallongeville S Ebrahim O Faergeman I Graham G Mancia V Manger Cats K Orth-Gomér J Perk K Pyörälä JL Rodicio S Sans V Sansoy U Sechtem S Silber T Thomsen D Wood Third joint task force of European and other societies on cardiovascular disease prevention in Clinical Practice, Eur Heart J 2003 24 1601 10 10.1016/S0195-668X(03)00347-6 12964575
27. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. L Wallentin RC Becker A Budaj CP Cannon H Emanuelsson C Held J Horrow S Husted S James H Katus KW Mahaffey BM Scirica A Skene PG Steg RF Storey RA Harrington PLATO Investigators A Freij M Thorsén, N Engl J Med 2009 361 1045 57 10.1056/NEJMoa0904327 19717846
28. A review of medicines for lowering blood pressure - A summary. N Hedberg J Jacob, Solna: Dental and Pharmaceutical Benefits Agency 2008 http://www.tlv.se/Upload/Genomgangen/review-blood-pressure.pdf [Accessed 17 April 10]
29. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. B Wettermark B Godman N Hedberg T-O Mellgren M Neovius T Kahan, Health Policy 2010 94 221 9 10.1016/j.healthpol.2009.09.014 19879009
30. The review of medicines for treating lipid disorders - A summary. G Eriksson D Lundin, Solna: Dental and Pharmaceutical Benefits Agency 2009 http://www.tlv.se/Upload/Genomgangen/summary-lipids.pdf [Accessed 24 April 09]
31. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. RA Hayward TP Hofer S Vijan, Ann Intern Med 2006 145 520 30 17015870
32. Effect of dronedarone on cardiovascular events in atrial fibrillation. SH Hohnloser HJ Crijns M van Eickels C Gaudin RL Page C Torp-Pedersen SJ Connolly ATHENA Investigators, N Engl J Med 2009 360 668 78 10.1056/NEJMoa0803778 19213680
33. Dronedarone for atrial fibrillation - an odyssey. PJ Zimetbaum, N Engl J Med 2009 360 1811 3 10.1056/NEJMp0902248 19403901
34. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). D Grady D Herrington V Bittner R Blumenthal M Davidson M Hlatky J Hsia S Hulley A Herd S Khan LK Newby D Waters E Vittinghoff N Wenger HERS Research Group, JAMA 2002 288 49 57 10.1001/jama.288.1.49 12090862 (Pubitemid 34705518)
35. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JE Rossouw GL Anderson RL Prentice AZ LaCroix C Kooperberg ML Stefanick RD Jackson SA Beresford BV Howard KC Johnson JM Kotchen J Ockene Writing Group for the Women's Health Initiative Investigators, JAMA 2002 288 321 33 10.1001/jama.288.3.321 12117397
36. Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. M Kendirci E Salem WJ Hellstrom, Ther Clin Risk Manag 2007 3 277 89 10.2147/tcrm.2007.3.2.277 18360636
37. International diffusion of new health technologies: a ten-country analysis of six health technologies. C Packer S Simpson A Stevens EuroScan: the European Information Network on New and Changing Health Technologies, Int J Technol Assess Health Care 2006 22 419 28 10.1017/S0266462306051336 16984674
38. Viagra: a success story for rationing? R Klein H Sturm, Health Aff (Millwood) 2002 21 177 87 10.1377/hlthaff.21.6.177 12442853
39. HIV epidemiology and the effects of antiviral therapy on long-term consequences. TC Quinn, AIDS 2008 22 Suppl 3 7 12 10.1097/01.aids.0000327510. 68503.e8 18845925
40. Emerging drug targets for antiretroviral therapy. JD Reeves AJ Piefer, Drugs 2005 65 1747 66 10.2165/00003495-200565130-00002 16114975
41. Rekommendation för screening av patientgrupper som fått blodtransfusion i Sverige före 1992. (Recommendation about screening of patients receiving blood transfusions in Sweden before 1992, In Swedish). National Board of Health and Welfare, Stockholm, Socialstyrelsen 2007
42. Current and future management of chronic hepatitis C infection. TJ Cross CG Antoniades PM Harrison, Postgrad Med J 2008 84 172 6 10.1136/pgmj.2008.068205 18424572
43. New drugs for chronic hepatitis B: a review. E Palumbo, Am J Ther 2008 15 167 72 10.1097/MJT.0b013e318155a191 18356637 (Pubitemid 351450781)
44. SWEDRES|2008 - A Report on Swedish Antimicrobial Utilisation and Resistance in Human Medicine. Swedish Strategic Programme against Antibiotic Resistance (STRAMA). J Struwe B Olsson-Liljequist editors., Swedish Institute for Infectious Disease Control. Stockholm 2008
45. Nedre urinvägsinfektion hos kvinnor. [Management of lower urinary tract infections in women]. Medical Products Agency, Stockholm: Medical Products Agency 2007 [In Swedish].
46. Pneumococcal conjugate vaccines for preventing otitis media. AG Jansen E Hak RH Veenhoven RA Damoiseaux PLEAAG Schilder EA Sanders, Cochrane Database Syst Rev 2009 2 D001480 19370566
47. Human papillomavirus vaccine: recommendations, issues and controversies. R Fisher DH Darrow M Tranter JV Williams, Curr Opin Pediatr 2008 20 441 5 10.1097/MOP.0b013e328305e298 18622201
48. Economic consequences to society of pandemic H1N1 influenza 2009 - preliminary results for Sweden. L Brouwers B Cakici M Camitz A Tegnell M Boman, Euro Surveill 2009 14 37 pii: 19333 19761738
49. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Lancet 2005 365 1687 717 10.1016/S0140-6736(05)66544-0 15894097
50. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) M Clarke AS Coates SC Darby C Davies RD Gelber J Godwin A Goldhirsch R Gray R Peto KI Pritchard WC Wood, Lancet 2008 371 29 40 10.1016/S0140-6736(08)60069-0 18177773
51. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. JS Ross EA Slodkowska WF Symmans L Pusztai PM Ravdin GN Hortobagyi, Oncologist 2009 25 320 68 10.1634/theoncologist.2008-0230
52. Cost of cancer care: issues and implications. NJ Meropol KA Schulman, J Clin Oncol 2007 25 180 6 10.1200/JCO.2006.09.6081 17210937
53. Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies. T Yau P Chan Y Ching Chan BC Wong R Liang RJ Epstein, Aliment Pharmacol Ther 2008 27 997 1005 10.1111/j.1365-2036. 2008.03684.x 18363897
54. Targeted drugs in chronic myeloid leukemia. J Gora-Tybor T Robak, Curr Med Chem 2008 15 3036 51 10.2174/092986708786848578 19075651
55. New drugs in multiple myeloma. JR Berenson O Yellin, Curr Opin Support Palliat Care 2008 2 204 10 10.1097/SPC.0b013e3283090475 18685422
56. Ten years of rituximab in NHL. MC Winter BW Hancock, Expert Opin Drug Saf 2009 8 223 35 10.1517/14740330902750114 19243307
57. Being NICE is not the problem! B Jonsson, Eur J Cancer 2009 45 1100 2 10.1016/j.ejca.2009.01.035 19268570
58. Emerging biologic drugs for the treatment of rheumatoid arthritis. F Puppo G Murdaca M Ghio F Indiveri, Autoimmun Rev 2005 4 537 41 10.1016/j.autrev.2005.04.016 16214092
59. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. SJ Tepper MJ Stillman, Headache 2008 48 1259 68 10.1111/j.1526-4610.2008.01214.x 18808506
60. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. AB Ettinger CE Argoff, Neurotherapeutics 2007 4 75 83 10.1016/j.nurt.2006.10.003 17199018
61. Questions and answers on recommendation for refusal of a change to the marketing authorisation for Lyrica. European Medicines Agency, http://www.emea.europa.eu/pdfs/human/opinion/LyricaQ&A-23113109en.pdf [Accessed 5 October 09]
62. The global market for ADHD medications. RM Scheffler SP Hinshaw S Modrek P Levine, Health Aff (Millwood) 2007 26 450 7 10.1377/hlthaff.26.2.450 17339673
63. Guidance for the treatment of neovascular age-related macular degeneration. UM Schmidt-Erfurth G Richard A Augustin WG Aylward F Bandello B Corcstegui J Cunha-Vaz A Gaudric A Leys RO Schlingemann European Society for Retina Specialists' Guidelines Committee (EURETINA), Acta Ophthalmol Scand 2007 85 486 94 10.1111/j.1755-3768.2007.00979.x 17655610 (Pubitemid 47163109)
64. Projecting future drug expenditures - 2008. JM Hoffman ND Shah LC Vermeulen F Doloresco P Grim RJ Hunkler KM Hontz GT Schumock, Am J Health Syst Pharm 2008 65 234 53 10.2146/ajhp070629 18216009
65. Projecting future drug expenditures-2009. JM Hoffman ND Shah LC Vermeulen F Doloresco PK Martin S Blake L Matusiak RJ Hunkler GT Schumock, Am J Health Syst Pharm 2009 66 237 57 10.2146/ajhp080636 19179637
66. Health spending projections through 2019: the recession's impact continues. CJ Truffer S Keehan S Smith J Cylus A Sisko JA Poisal J Lizonitz MK Clemens, Health Aff (Millwood) 2010 29 522 9 10.1377/hlthaff.2009.1074 20133357
67. National health spending in 2006: a year of change for prescription drugs. A Catlin C Cowan M Hartman S Heffler National Health Expenditure Accounts Team, Health Aff (Millwood) 2008 27 14 29 10.1377/hlthaff.27.1.14 18180476
68. The demise of the blockbuster? DM Cutler, N Engl J Med 2007 356 1292 3 10.1056/NEJMp078020 17392299
69. When the party's over. M Wadman, Nature 2007 445 13 10.1038/445013a 17203035
70. Financial incentives and prescribing in Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Edited by: Elias Mossialos, Monique Mrazek, Tom Walley. Open University Press; 2004. ISBN 0 335 21465 7(pb) 0 335 21466 5 (hb)(hb)
71. Pharmaceutical policies: effects of financial incentives for prescribers (Review). H Sturm A Austvoll-Dahlgren M Aaserud AD Oxman C Ramsay A Vernby JP Kösters, Cochrane database of Systematic Reviews 2007 3 D006731 DOI: 10.1002/14651858.CD006731 (Pubitemid 351805597)
72. Prescribing incentive schemes: a useful approach? AR Mason MF Drummond JA Hunter AK Towse J Cooke, Appl Health Econ Health Policy 2005 4 111 7 10.2165/00148365-200504020-00005 16162030
73. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. H Melander J Ahlqvist-Rastad G Meijer B Beermann, BMJ 2003 326 1171 3 10.1136/bmj.326.7400.1171 12775615
74. Assessing the accuracy of forecasting: applying standard diagnostic assessment tools to a health technology early warning system. S Simpson C Hyde A Cook C Packer A Stevens, Int J Technol Assess Health Care 2004 20 3 381 4 10.1017/S0266462304001229 15446770
75. The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JH Barton EJ Emanuel, JAMA 2005 294 2075 82 10.1001/jama.294.16.2075 16249422
76. European Commission takes on Big Pharma. A den Exter, Lancet 2009 374 599 600 10.1016/S0140-6736(09)61370-2 19699998
77. Enhancing the rational use of new medicines across European health care systems. S Garattini V Bertelé B Godman A Haycox B Wettermark LL Gustafsson The Piperska Group, Eur J Clin Pharmacol 2008 64 1137 8 10.1007/s00228-008-0537-z 18688606
78. Swedish registers to examine drug safety and clinical issues in RA. J Askling CM Fored P Geborek LT Jacobsson R van Vollenhoven N Feltelius S Lindblad L Klareskog, Ann Rheum Dis 2006 65 707 12 10.1136/ard.2005.045872 16414975
79. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. FR Lichtenberg, Int J Health Care Finance Econ 2005 5 47 73 10.1007/s10754-005-6601-7 15714263
80. Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. FR Lichtenberg, Health Econ 2009 18 519 34 10.1002/hec.1382 18634121